Indian Journal of Animal Research

  • Chief EditorK.M.L. Pathak

  • Print ISSN 0367-6722

  • Online ISSN 0976-0555

  • NAAS Rating 6.50

  • SJR 0.263

  • Impact Factor 0.4 (2024)

Frequency :
Monthly (January, February, March, April, May, June, July, August, September, October, November and December)
Indexing Services :
Science Citation Index Expanded, BIOSIS Preview, ISI Citation Index, Biological Abstracts, Scopus, AGRICOLA, Google Scholar, CrossRef, CAB Abstracting Journals, Chemical Abstracts, Indian Science Abstracts, EBSCO Indexing Services, Index Copernicus
Submit

Research Article

Indian Journal of Animal Research, volume 53 issue 9 (september 2019) : 1229-1233

In-silico approach to determine the possibility of a recombinant broad-spectrum vaccine for bluetongue disease

J. Shiva Jyothi, Kalyani Putty, Sunil. R. Patil, Y. Narsimha Reddy
1College of Veterinary Science, P.V.N.R. Telangana Veterinary University, Rajendrangar, Hyderabad-500 030, Telangana, India.
Cite article:- Jyothi Shiva J., Putty Kalyani, Patil R. Sunil., Reddy Narsimha Y. (2018). In-silico approach to determine the possibility of a recombinant broad-spectrum vaccine for bluetongue disease. Indian Journal of Animal Research. 53(9): 1229-1233. doi: 10.18805/ijar.B-3635.

ABSTRACT

Bluetongue (BT) disease caused by BT virus (BTV) is an acute haemorrhagic disease of domesticated and wild ruminants. 29 BTV serotypes have been identified so far throughout the world with 24 circulating in India conferring no cross protective immunity. Hence, the objective of the current study was to investigate the possibility of developing a recombinant subunit protein based vaccine for BT that is cross protective to all the known serotypes of BTV. VP2 is a major serotype determining protein and vaccination with VP2 was known to induce neutralizing antibody response. Since BTV circulates as 29 immunologically distinct serotypes, the current study aimed to identify conserved region of VP2. The amino acid sequence alignment showed that although VP2 was very variable among serotypes, several regions were relatively more conserved between serotypes; most conserved region (cVP2) of which was evident from 338-383aa. Moreover, selection pressure analysis revealed that all the codons in cVP2 region were under strong negative selection (dN/dS=0.16) suggesting strong structural and functional constraints on cVP2. In addition, two MHCI, MHCII each, and three B cell epitopes were predicted based on the physicochemical properties of the amino acids in cVP2 region. This suggests strong immunogenicity of cVP2 making it a suitable vaccine candidate. Taken together, cVP2 appears to be a promising target for a broad-spectrum subunit vaccine moiety for BT that can confer protection against the available serotypes of BTV. Since all the structural proteins of BTV will not be used in such subunit vaccines, observations from current study can also be extended to develop a marker vaccine for DIVA against BT. 

REFERENCES

  1. Anderson J, Hagglund S, Breard E, et al. (2013). Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle. Clin Vaccine Immunol. 20:1115–22. 
  2. Anderson J, Hagglund S, Breard E, et al. (2014). Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle. Vaccine 32:6614–21.
  3. Baetza H.J. (2014). Eradication of bluetongue disease in Germany by vaccination. Vet Immunol Immunopathoogyl 158:116–9.
  4. Barh, D., Misra, A.N., Kumar, A., (2010). In silico identification of dual ability of N. gonorrhoeae ddl for developing drug and vaccine against pathogenic Neisseria and other human pathogens. J. Proteomics Bioinform. 3, 82–90. doi:http://dx. doi.org/10.4172/    jpb.1000125.
  5. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, et al (2017).Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. 25(4):672-8. Epub 2006 Sep 5.
  6. Breard E, Belbis G, Viarouge C, et al. (2015). Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines. Vaccine 33:512–8.
  7. Carpi G, Holmes EC, Kitchen A (2010) The evolutionary dynamics of bluetongue virus. J Mol Evol. 70(6):583-92. doi: 10.1007/    s00239-010-9354-y. Epub 2010 Jun
  8. Delport W, Poon AF, Frost SD, Kosakovsky Pond S L. Datamonkey (2010): A suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics. 26(19):2455-7. doi: 10.1093/bioinformatics/btq429. Epub 2010 Jul 29.
  9. DeMaula, C. D., Bonneau, K. R. and MacLachlan, N. J. (2000). Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies. Virus Res 67, 59–66.
  10. DeMaula, C. D., Heidner, H. W., Rossitto, P. V., Pierce, C. M. and MacLachlan, N. J. (1993). Neutralization determinants of United States bluetongue virus serotype ten. Virology 195: 292–296.
  11. Edgar RC1(2004) MUSCLE: a multiple sequence alignment method with reduced time and spacecomplexity. BMC Bioinformatics. 19;5:113.
  12. Forzan M.Christoph, Wirblich, and Polly Roy, (2004) A capsid protein of nonenveloped Bluetongue virus exhibits membrane fusion activity. Proc. Natl. acad. Sci. USA 101: 2100-2105.
  13. Gould AR , Hyatt AD, Eaton BT. (1988) Morphogenesis of a bluetongue virus variant with an aminoacid alteration at a neutralization site in the outer coat protein, VP2. Virology. 1988Jul;165(1):23-32.
  14. Hassan, S. Wilbrlich H C, Forzan M, Roy P. (2001) Expression and functional characterization of blue tongue virus VP5 protein: role in cell entry. J. virol.75:8356-8367.
  15. Hemadri D, Maan S, Chanda MM, Rao PP, Putty K, Krishnajyothi Y, Reddy GH, Kumar V, Batra K, Reddy YV, Maan NS. 2017 Dual Infection with Bluetongue Virus Serotypes and First Time Isolation of Serotype 5 in India. Transboundary and Emerging Diseases. 64:1912-1917.
  16. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M    (2008)NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2009. 61(1):1-13. doi: 10.1007/s00251-008-0341-z. (1987).
  17. Huismans H, Van Der Walt NT, Cloete M, Erasmus BJ. (1987) Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Virology, 61:3589-3595.
  18. Inumaru S, Roy P. (1987) Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector. Virology. 157(2):472.
  19. Karthika Lakshmi, Kalyani Putty, Satya Samparna Raut, Sunil R. Patil, P. P. Rao, B. et al (2018). Standardization and application of real-time polymerase chain reaction for rapid detection of bluetongue virus Veterinary World,.11/ 7.EISSN: 2231-0916
  20. Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, Lundegaard C, Sette ALund O, (2012). Immune epitope database analysis resource.Nucleic Acids Res. 40:W525-30. doi: 10.1093/nar/gks438.    Epub 2012 May 18.
  21. Kosakovsky Pond SL, Frost SD (2008) Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol.;22(5):1208-22. Epub 2005Feb 9.
  22. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD GARDL2006) A geneticalgorithm for recombination detection Bioinformatics.;22(24):3096-8.
  23. Krishnajyothi Y, Maan S, Kandimalla K, Maan NS, Tutika RB, Reddy YV, Kumar A Mrunalini N, Reddy GH, Putty K, Ahmed SM. (2016). Isolation of bluetongue virus 24 from India–an exotic serotype to Australasia. Transboundary and Emerging Diseases.63:360-364.
  24. Lobato Z. I, Coupar B.E, Gray C.P, Lunt R, Andrew ME. (1997) Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.Vet Immunol Immunopathol, . 59: 293-­ 309, Nov. 
  25. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities forpeptides of length 8-11. ;36 
  26. Maan, S., Maan, N.S., Belaganahalli, M.N., Potgieter, A.C., Kumar, V., Batra, K., Wright, I.M., et al. (2016) Development and evaluation of realtime RT-PCR assays for detection and typing of bluetongue virus. PLoS One, 11: e0163014. 
  27. Maclachlan, N.J. and Mayo, C.E. (2013) Potential strategies for control of bluetongue, a globally emerging, Culicoidestransmitted viral disease of ruminant livestock and wildlife. Antiviral Res. 99: 79-90. 
  28. MacLachlan, N.J., (1994). The pathogenesis and immunology of bluetongue virus infection of ruminants. Comp. Immunol. Microbiol. Infect. Dis. 17, 197–206.
  29. Marin-Lopez A, Otero-Romero I, de la Poza F, et al. (2014). VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice. Antiviral Res 110:42–51.
  30. Mertens PPC, Burroughs JN, Walton A, Welby MP, Fu H, O’Hara RS, Brookes SM, Mellor PS: (1995) Enhanced infectivities of modified bluetongue virus for two insect cell lines for two Culicoides vector species. Virology, 217:582-593.
  31. Mertens, P P., Brown, F., Sangar, D.V., (1984). Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology 13: 207–217.
  32. Mohd Jaafar F, Belhouchet M, Vitour D, et al. (2014). Immunization with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect alpha/beta interferonreceptor knock-out (IFNAR(-/-) mice from homologous lethal challenge. Vaccine 32:4059–67.
  33. Murphy, F A., Fauquet, C.M., Bishop, D.H.L., Ghabrial, S.A., Jarvis, A.W., Martelli,G.P.,Mayo, M.A., Summers, M.D., (1995). Virus taxonomy, classification and nomenclature of viruses (Sixth Report of the International Committee on Taxonomy of Viruses). Arch. Virol. Suppl. 10: 412–414.
  34. Nielsen, M. and Andreatta, M., (2016). NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Medicine, 8(1), p.33.
  35. Pioz M, Guis H, Pleydell D, et al. (2014). Did vaccination slow the spread of bluetongue in France? PLoS One 9:e85444.
  36. Roy P, French, T., Erasmus, B.J., (1992). Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10, 28– 32.
  37. Roy P, Urakawa T, Van Dijk AA, Erasmus BJ. (1990) Recombinant virus vaccine for bluetonguedisease in sheep. J Virol (5):1998–2003.
  38. Schulz, C., Bréard, E., Sailleau, C., Jenckel, M., Viarouge, C., Vitour, D., Palmarini, M., Gallois, M., et al. (2016) Bluetongue virus serotype 27: detection and characterization of two novel variants in Corsica, France. J. Gen. Virol. 97: 2073-2083.
  39. Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, Peters B Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 2008 25;4:2. doi:    10.1186/1745-7580-4-2.
  40. Spruell, J, (1905). Malarial catarrhal fever (bluetongue) of sheep in South Africa. J. Comp. Pathol. Ther. 18, 321– 337.
  41. Suzuki Y, Gojobori T. (1999) A method for detecting positive selection at single amino acid sites. Mol Biol Evol. 16(10):1315-28.
  42. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 28:2731–2739.
  43. Verwoerd, D W., Els, H.J., De Villiers, E.M., Huismans, H., 1972. Structure of the bluetongue virus capsid. J. Virol. 10: 783–794.
  44. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 4(4):e1000048. doi: 10.1371/journal.pcbi.1000048.
  45. Zhang, N., MacLachlan, N. J., Bonneau, K. R., Zhu, J., Li, Z., Zhang, K., Zhang, F., Xia, L. and Xiang, W. (1999). Identification of seven serotypes of bluetongue virus from the People’s Republic of China. Vet Rec 145: 427–429. 
Reviewed By

Download Article
In this Article
    Contact us
    Follow us

    Editorial Board

    View all (0)